Feb 10 (Reuters) - Palvella Therapeutics PVLA.O:
PALVELLA THERAPEUTICS TO EXPAND PHASE 3 SELVA CLINICAL TRIAL OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) FOR THE TREATMENT OF MICROCYSTIC LYMPHATIC MALFORMATIONS TO INCLUDE THE YOUNGER PEDIATRIC POPULATION, CHILDREN 3 TO 5 YEARS OLD
PALVELLA THERAPEUTICS INC - TO REPORT PHASE 3 TRIAL RESULTS IN Q1 2026
Source text: ID:nGNX6B2g7s
Further company coverage: PVLA.O